search
Back to results

Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects (MAPPAC)

Primary Purpose

Acute Appendicitis

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Ertapenem followed by levofloxacin and metronidazole
Moxifloxacin
Appendectomy
Placebo
Sponsored by
Turku University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Acute Appendicitis focused on measuring Uncomplicated acute appendicitis, Complicated acute appendicitis, Antibiotic therapy, Microbiological etiology

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-60 years
  • CT confirmed uncomplicated or complicated acute appendicitis
  • Ability to give consent to participate in the study

Exclusion Criteria:

  • Age under 18 years or over 60 years
  • Pregnancy or lactation
  • Allergy to contrast media or iodine
  • Allergy or contraindication to antibiotic therapy
  • Renal insufficiency
  • Metformin medication
  • Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication)
  • Inability to co-operate and give informed consent

Sites / Locations

  • Turku University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Other

Other

Active Comparator

Arm Label

I.v. + p.o. antibiotics (APPAC II)

P.o. moxifloxacin (APPAC II)

Placebo treatment (APPAC III)

Surgery (complicated appendicitis)

Surgery (uncomplicated appendicitis)

I.v. + p.o. antibiotics (APPAC III)

Arm Description

Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.

Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.

Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.

Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.

Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.

Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.

Outcomes

Primary Outcome Measures

Microbiology in the etiology of acute appendicitis
Differences in the microbiological etiology of complicated and uncomplicated appendicitis

Secondary Outcome Measures

Effects of antimicrobial treatment on gut microbiota
Determining the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment evaluated by rectal swabs pre- and post treatment
Effects of hospital stay duration on the AMR reservoir of the gut microbiota
The effect of length of hospital stay (days) on the AMR reservoir of gut microbiota and colonization occurrence evaluated by analysing rectal swabs microbiota pre- and post-treatment at 0, 1 and 3 days.

Full Information

First Posted
August 2, 2017
Last Updated
November 9, 2020
Sponsor
Turku University Hospital
Collaborators
Tampere University Hospital, Oulu University Hospital, Kuopio University Hospital, Helsinki University Central Hospital, Jyväskylä Central Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03257423
Brief Title
Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects
Acronym
MAPPAC
Official Title
Acute Appendicitis and Microbiota - Ethology of Appendicitis and Effects of the Antimicrobial Treatment - The MAPPAC (Microbiology Appendicitis Acuta) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 4, 2017 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Turku University Hospital
Collaborators
Tampere University Hospital, Oulu University Hospital, Kuopio University Hospital, Helsinki University Central Hospital, Jyväskylä Central Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.
Detailed Description
Appendectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota. Gut microbiota is an extremely complex ecosystem with both high bacterial density and diversity. Recent scientific evidence emphasizes that the symbiosis between the host and the balanced gut microbiota supports good health, and contributes to various biochemical and metabolic functions occurring in host's body. The possible role of the somehow distorted gut microbiota composition in addition to its metabolites in the etiopathogenesis of many diseases such as allergy, inflammatory bowel disease, type 1 diabetes and obesity related disorders, has been recently proposed. Further, detected alterations and perturbations both in the gut microbiota composition and functionality have been linked to the development of various malignancies such as colorectal cancer, gastric cancer and hepatocellular carcinoma. To date, the role of the microbes and especially the members of the commensal microbiota with their structural compartments and metabolites in the pathogenesis and etiology of appendicitis have not been clarified in detail, despite the recent knowledge that uncomplicated acute appendicitis could be treated by antibiotic treatments alone. Further, there is only limited amount of evidence on the appendix microbial composition in humans. Microbial overgrowth has been speculated to serve as a secondary consequence in appendicitis. However, recent accumulating evidence suggests that primary bacterial infection may actually be an initiating event in the pathogenesis of the disease. Interestingly, it has been postulated that the appendix could serve as a microbial reservoir for repopulating the gastrointestinal tract in times of necessity thus gut microbiota may act as a source for these pathogenic intruders. Further it has been reported that certain members of the gram negative Fusobacteria especially F. nucleatum and necrophorum are present in most appendicitis samples. Additionally, antimicrobial resistance (AMR) is considered an increasing global threat. According to the WHO (World Health Organisation), in 2050s more people will be killed by AMR bacteria than by all cancers.The use of antimicrobials in humans and especially in animal health care and production industry are the major causes of increasing AMR worldwide; the prudent use of antimicrobials is essential to prevent increasing AMR. Antimicrobials are known to decrease the gut microbiota diversity, richness and species variation and cause the perturbation of its overall balance and even a short-term antimicrobial treatment has a long-term impact on its composition underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. The bacterial composition of the complicated appendix will be compared to the gut microbiota composition determined from the fecal sample collected from the same individual. Additionally, these results will be compared to the gut microbiota composition of patients with uncomplicated acute appendicitis. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT). The bacterial composition and AMR reservoir of the gut microbiota will be evaluated both pre and post treatment in patients receiving antibiotic or placebo treatment for uncomplicated acute appendicitis. Additionally, the recovery of gut microbiota composition and disappearance of AMR will be evaluated. We will compare two variations (i.v.and p.o.) of antibiotic treatment with the placebo treatment. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota. According to the study protocols of the APPAC II and III trials, patients will spend either 1 or 3 days in the hospital in order to receive treatment before continuing the selected treatment at home. We will evaluate the effects of length of stay on the AMR reservoir of gut microbiota as well as evaluating if and when possible colonization occurs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Appendicitis
Keywords
Uncomplicated acute appendicitis, Complicated acute appendicitis, Antibiotic therapy, Microbiological etiology

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients are enrolled in conjuction with APPAC II (NCT03236961) and APPAC III (NCT 03234296) trials, all patients with uncomplicated or complicated acute appendicitis are evaluated for MAPPAC enrollment. MAPPAC study groups: complicated acute appendicitis (samples: rectal swabs, serum, removed appendix), APPAC II patients in two groups according to APPAC II randomized antibiotic therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic treatment failure or appendicitis recurrence also removed appendix), APPAC III patients in two groups according to APPAC III randomized group of antibiotc or placebo therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic or placebo treatment failure or appendicitis recurrence also removed appendix), and patients with uncomplicated acute appendicitis declining to participate in APPAC II or III trials undergoing appendectomy
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
I.v. + p.o. antibiotics (APPAC II)
Arm Type
Active Comparator
Arm Description
Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Arm Title
P.o. moxifloxacin (APPAC II)
Arm Type
Active Comparator
Arm Description
Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
Arm Title
Placebo treatment (APPAC III)
Arm Type
Placebo Comparator
Arm Description
Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
Arm Title
Surgery (complicated appendicitis)
Arm Type
Other
Arm Description
Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
Arm Title
Surgery (uncomplicated appendicitis)
Arm Type
Other
Arm Description
Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
Arm Title
I.v. + p.o. antibiotics (APPAC III)
Arm Type
Active Comparator
Arm Description
Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
Intervention Type
Drug
Intervention Name(s)
Ertapenem followed by levofloxacin and metronidazole
Intervention Description
Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
Intervention Type
Drug
Intervention Name(s)
Moxifloxacin
Intervention Description
Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
Intervention Type
Procedure
Intervention Name(s)
Appendectomy
Intervention Description
Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
Primary Outcome Measure Information:
Title
Microbiology in the etiology of acute appendicitis
Description
Differences in the microbiological etiology of complicated and uncomplicated appendicitis
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Effects of antimicrobial treatment on gut microbiota
Description
Determining the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment evaluated by rectal swabs pre- and post treatment
Time Frame
1 year
Title
Effects of hospital stay duration on the AMR reservoir of the gut microbiota
Description
The effect of length of hospital stay (days) on the AMR reservoir of gut microbiota and colonization occurrence evaluated by analysing rectal swabs microbiota pre- and post-treatment at 0, 1 and 3 days.
Time Frame
3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-60 years CT confirmed uncomplicated or complicated acute appendicitis Ability to give consent to participate in the study Exclusion Criteria: Age under 18 years or over 60 years Pregnancy or lactation Allergy to contrast media or iodine Allergy or contraindication to antibiotic therapy Renal insufficiency Metformin medication Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication) Inability to co-operate and give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paulina Salminen, MD, PhD
Organizational Affiliation
Turku University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Turku University Hospital
City
Turku
Country
Finland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36240181
Citation
Vanhatalo S, Munukka E, Kallonen T, Sippola S, Gronroos J, Haijanen J, Hakanen AJ, Salminen P. Appendiceal microbiome in uncomplicated and complicated acute appendicitis: A prospective cohort study. PLoS One. 2022 Oct 14;17(10):e0276007. doi: 10.1371/journal.pone.0276007. eCollection 2022.
Results Reference
derived
PubMed Identifier
31494621
Citation
Vanhatalo S, Munukka E, Sippola S, Jalkanen S, Gronroos J, Marttila H, Eerola E, Hurme S, Hakanen AJ, Salminen P; APPAC collaborative study group. Prospective multicentre cohort trial on acute appendicitis and microbiota, aetiology and effects of antimicrobial treatment: study protocol for the MAPPAC (Microbiology APPendicitis ACuta) trial. BMJ Open. 2019 Sep 6;9(9):e031137. doi: 10.1136/bmjopen-2019-031137.
Results Reference
derived

Learn more about this trial

Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects

We'll reach out to this number within 24 hrs